Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) – Stock analysts at Oppenheimer dropped their Q2 2022 EPS estimates for Intercept Pharmaceuticals in a research report issued on Sunday, May 8th. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($0.70) for the quarter, down from their previous estimate of ($0.56). Oppenheimer also issued estimates for Intercept Pharmaceuticals’ Q3 2022 earnings at ($0.21) EPS, Q4 2022 earnings at ($0.80) EPS, FY2022 earnings at ($2.30) EPS, FY2024 earnings at ($5.07) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at $0.53 EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last posted its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.31. During the same period in the previous year, the business posted ($1.22) EPS.
ICPT stock opened at $18.77 on Wednesday. The firm has a market capitalization of $557.71 million, a PE ratio of -8.34 and a beta of 1.27. Intercept Pharmaceuticals has a twelve month low of $11.60 and a twelve month high of $22.36. The stock has a 50-day simple moving average of $16.39 and a two-hundred day simple moving average of $16.44.
A number of hedge funds and other institutional investors have recently modified their holdings of ICPT. Adage Capital Partners GP L.L.C. bought a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $20,086,000. Point72 Asset Management L.P. bought a new position in Intercept Pharmaceuticals during the third quarter valued at approximately $10,376,000. Millennium Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at approximately $9,117,000. Eventide Asset Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at approximately $5,334,000. Finally, Balyasny Asset Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $3,575,000. Institutional investors and hedge funds own 83.44% of the company’s stock.
About Intercept Pharmaceuticals (Get Rating)
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
- Get a free copy of the StockNews.com research report on Intercept Pharmaceuticals (ICPT)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.